Demo test Trial  

Test Comment here..

Anonymous Patient  

virtualtesting  

(*) Coronary heart disease (CHD), cerebrovascular manifestation, peripheral arterial occlusive disease (PAOD) (**) For cardiovascular events (e.g. diabetes mellitus, renal function glomerular filtration rate (GFR) < 60 ml/min) Exclusion Criteria: - Planned or existing pregnancy, cancer, drug or alcohol abuse, dementia, or general inability to understand the content of the …

Trial T2  

QA Comment

Fatty Liver  

[1] Complications may include cirrhosis, liver cancer, and esophageal varices.[1][3] There are two types of fatty liver disease: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease.

European Study of Opioid Induced Constipation (E-StOIC)

Constipation is common (40-90%) in advanced cancer patients , and has a significant negative impact on quality of life. The aetiology of constipation is often multifactorial in advanced cancer patients.

Immune Score Based Radiomics in Nasopharyngeal Carcinoma

In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely.

Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions (IPMRA)  

As of 2019, the CA-SFM (Comité de l'Antibiogramme de la Société Française de Microbiologie) recommends that the letter "I" or the term "intermediate" on antibiotic antibiograms.

Skin Toxicity by Oncological Therapies (SKINTOX)

This is a multicenter, retrospective and prospective observational study. The project involves the collection of clinical data of patients treated with oncological therapies, to evaluate skin toxicities related to oncological treatment.

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.